GleamWall
中文EN

SCNI Scinai Immunotherapeutics Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY99.2%
TTM net income YoY-273.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-202.3%
Operating margin-575.3%
Net margin-633.6%
FCF margin-461.9%
EBITDA margin-466.9%

Returns

ROE-91.9%
ROA-66.3%
ROIC (approx.)-82.4%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.31M$658,000
Cost of revenue$3.96M$1.24M
Gross profit-$2.65M-$580,000
R&D expense$2.37M$5.53M
SG&A expense$2.52M$2.53M
Operating income-$7.54M-$8.64M
Net income-$8.31M$4.80M
EBITDA-$6.12M-$6.99M
EPS (diluted)——
Weighted avg. shares (diluted)9.34B3.23B
Balance sheet
Cash & equivalents$1.66M$1.96M
Receivables$73,000$83,000
Current assets$2.05M$2.39M
PP&E, net$7.79M$9.19M
Total assets$11.63M$13.45M
Current liabilities$1.58M$1.81M
Total liabilities$3.52M$3.47M
Shareholders' equity$8.10M$9.98M
Shares outstanding13.87B3.41B
Cash flow statement
Operating cash flow-$6.03M-$6.33M
Capital expenditure$24,000$12,000
Free cash flow-$6.05M-$6.35M
Investing cash flow-$24,000-$12,000
Financing cash flow$5.77M$3.44M
Depreciation & amortization$1.42M$1.65M
Stock-based compensation$303,000$682,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.